Woodline Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.7M Buy
+482,264
New +$8.69M 0.03% 563
2025
Q2
– Sell
-1,504,095
Closed -$12.6M – 919
2025
Q1
$12.6M Buy
1,504,095
+937,035
+165% +$7.82M 0.08% 321
2024
Q4
$4.49M Sell
567,060
-1,037,471
-65% -$8.7M 0.03% 507
2024
Q3
$13.3M Buy
1,604,531
+289,508
+22% +$2.26M 0.11% 250
2024
Q2
$8.35M Buy
1,315,023
+626,917
+91% +$3.98M 0.08% 274
2024
Q1
$4.17M Buy
+688,106
New +$3.88M 0.04% 378

Other funds holding AMRX

Woodline Partners's AMRX Position: Q3 2026 in Review

Woodline Partners opened a new position in Amneal Pharmaceuticals (AMRX) in Q3 2026: 482,264 shares worth $9.7M. The stake represents 0.03% of the portfolio and ranks #563 among its holdings. This is a return to the name: Woodline Partners previously reported a position in AMRX as recently as Q1 2025.

Woodline Partners first reported a position in AMRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $13.3M in Q3 2024. 334 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Woodline Partners held 482,264 shares of Amneal Pharmaceuticals worth $9.7M as of Q3 2026.
  • Amneal Pharmaceuticals was a new Woodline Partners position in Q3 2026.
  • Amneal Pharmaceuticals made up 0.03% of Woodline Partners's portfolio in Q3 2026, its #563 holding.
  • Woodline Partners first reported a position in Amneal Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Woodline Partners's Amneal Pharmaceuticals position peaked at $13.3M in Q3 2024.
  • 334 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.